Team:EPF Lausanne/Calendar/23 September 2013

From 2013.igem.org

(Difference between revisions)
 
(2 intermediate revisions not shown)
Line 4: Line 4:
''Measuring GFP expression with a plate reader'' <BR>
''Measuring GFP expression with a plate reader'' <BR>
-
-Again we let the bacteria with the three different promoters grow in media with different pHs. Only the constitutive promoter had a very strong GFP expression, which was as expected, since it served as positive control. But again neither the hya nor the cad promoters seemed to be induced. Furthermore, the bacteria in the acidic ph (at 5.5) died very quickly.
+
-Again we let the bacteria with the three different promoters grow in media with different pHs. Only the constitutive promoter had a very strong GFP expression, which was as expected, since it served as positive control. But again neither the hya nor the cad promoters seemed to be induced. Furthermore, the bacteria in the acidic pH (at 5.5) died very quickly.
<BR><BR>
<BR><BR>
Line 14: Line 14:
<font size = "4"> Human practice </font> <BR>
<font size = "4"> Human practice </font> <BR>
-
 
''Kit''<BR>
''Kit''<BR>
-
=( we don't get any results in following the BioBuilder protocol.
+
Making competent cells and transformation with AraC and constitutive-GFP plasmids according to the BioBuilder protocol. <BR>
-
 
+
{{Template:EPFL2013Footer}}
{{Template:EPFL2013Footer}}

Latest revision as of 22:26, 4 October 2013

Taxi.Coli: Smart Drug Delivery iGEM EPFL

Header

Sensing-Effector

Measuring GFP expression with a plate reader
-Again we let the bacteria with the three different promoters grow in media with different pHs. Only the constitutive promoter had a very strong GFP expression, which was as expected, since it served as positive control. But again neither the hya nor the cad promoters seemed to be induced. Furthermore, the bacteria in the acidic pH (at 5.5) died very quickly.

Nanoparticles

Microscopy of Nanoparticles
Microscopy of the biotinylated FITC-D and rGFP loaded NPs.

Human practice
Kit
Making competent cells and transformation with AraC and constitutive-GFP plasmids according to the BioBuilder protocol.